Q3 2024 Achieve Life Sciences Inc Earnings Call Transcript
Key Points
- Achieve Life Sciences Inc (ACHV) received FDA breakthrough therapy designation for Cytisinicline for vaping cessation, enhancing regulatory support.
- The company completed enrollment for the ORCA-OL safety trial ahead of schedule, demonstrating efficient trial management.
- Cytisinicline is positioned to be the first new prescription smoking cessation drug in nearly 20 years, with promising efficacy and tolerability.
- Achieve Life Sciences Inc (ACHV) has a strategic plan for a digital-first commercial launch, leveraging data-driven approaches to target primary care physicians and patients effectively.
- The company successfully refinanced its SVB loan, securing up to $20 million in availability, which supports financial stability and future operations.
- Achieve Life Sciences Inc (ACHV) reported a net loss of $12.5 million for the third quarter, an increase from the previous year, indicating rising operational costs.
- The company faces challenges in transitioning from a clinical development focus to a commercial entity, requiring significant strategic and operational shifts.
- There is uncertainty regarding the timeline and cost of the upcoming phase three clinical trial for vaping cessation, which could impact financial planning.
- The synthetic Cytisinicline development process is ongoing with no definitive timeline for completion, potentially delaying product diversification.
- Achieve Life Sciences Inc (ACHV) must navigate complex regulatory requirements for potential adolescent trials and new nicotine products like tobacco pouches, which could complicate future development plans.
Greetings and welcome to the Achieve Life Sciences third quarter, 2024 earnings conference call and webcast. At this time, all participants are in a listen-only mode, a question and answer session will follow the formal presentation. And as a reminder, this conference is being recorded.
I would now like to turn the call over to Nicole Jones, Achieve's investor relations.
Thank you, Nicole. You may begin.
Thank you, operator. Good afternoon, everyone and thank you for joining us today. From Achieve Life Sciences we are joined by Rick Stewart, Chief Executive Officer, Dr Cindy Jacobs, President and Chief Medical Officer, Jerry Wan, principal accounting officer and Jamie Xinos, Chief Commercial Officer. Management will be available for a Q&A session following today's prepared remarks before we begin. I'd like to remind everyone that today's conference call contains forward-looking statements based on current expectations. These statements are only predictions and actual results may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investorsā 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
